Liquid Hemopexin Formulation for High-Concentration Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Purified hemopexin preparations suffer from poor stability as a liquid formulation, which limits their therapeutic potential in managing heme-mediated oxidative tissue damage during pathological conditions like hemolysis.
Innovation Solution
A stable liquid formulation of hemopexin is developed, comprising at least 50 mg/ml hemopexin content, 15 mM phosphate buffer, pH 5.8 to 8, and at least 50 mM sodium chloride, enhancing its stability for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If purified hemopexin is prepared as a liquid formulation for therapeutic use, then its therapeutic potential in managing heme-mediated oxidative tissue damage is improved, but its stability is poor
Solution Approach 1:
The patent applies parameter changes by optimizing the pH range (5.8 to 8.0) and ionic strength (sodium chloride concentration) of the liquid formulation to enhance hemopexin stability. These parameter adjustments prevent protein degradation while maintaining therapeutic efficacy, directly resolving the contradiction between stability and therapeutic potential
2Quantity of substance
If hemopexin concentration is increased to enhance therapeutic effect, then its ability to bind and transport heme is improved, but formulation stability deteriorates
Solution Approach 1:
The patent enables high hemopexin concentrations (at least 50 mg/ml) to be maintained in liquid formulation by optimizing pH and ionic strength parameters. This prevents protein aggregation and degradation that would normally occur at such concentrations, allowing therapeutic efficacy to be maximized without sacrificing stability
3Object-affected harmful factors
If hemopexin is administered to treat pathological hemolysis, then heme-induced toxicity is reduced, but the complexity of formulation development increases
Solution Approach 1:
The patent simplifies formulation development by identifying a specific pH range (5.8 to 8.0) and ionic strength requirement for hemopexin stability. These clear parameter specifications provide a straightforward development pathway, avoiding the need for complex formulation strategies while ensuring therapeutic effectiveness against heme-induced toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains hemopexin's stability under various conditions, ensuring its effectiveness in binding and transporting heme, thereby reducing heme-induced toxicity and oxidative tissue damage.
Implementation Method 1
Residues His213 and His266 coordinate the heme iron atom giving a stable bis-histidyl complex, similar to haemoglobin
Implementation Method 2
at least 15 mM phosphate buffer; a pH from 5.8 to 8
Implementation Method 3
at least 50 mM sodium chloride
Data Source
AI summary
The present invention relates generally to a stable liquid formulation of purified hemopexin comprising: (a) a hemopexin content of at least 50 mg/mL; (b) at least 15 mM phosphate buffer; (c) a pH from 5.8 to 8; and (d) at least 50 mM sodium chloride; and uses thereof.